JMP Securities initiated coverage of Simulations Plus with a Market Perform rating and no price target. The company has a deep history in model informed drug development and its recent Pro-ficiency acquisition doubles its addressable market, the analyst tells investors in a research note. However, the firm believes the current share price adequately contemplates Simulations Plus’s growth trajectory and current demand backdrop.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLP:
- Simulations Plus announces new cosmetics safety research project with ICCS
- Craig-Hallum remains bullish on Simulations Plus following quarterly results
- Simulations Plus cuts FY24 EPS view to 54c-56c from 66c-68c
- Simulations Plus Q3 Financials: Expectations and Uncertainties
- Simulations Plus reports Q3 EPS 15c, consensus 15c